Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > MHLW Expert Panel on Comprehensive Measures for Pharmaceuticals
MHLW Expert Panel on Comprehensive Measures for Pharmaceuticals
-
MHLW Expert Panel Sorts Out Discussion Points for Full Debate; Focus on Innovation, Stable Supply, and Margins
October 13, 2022
-
Wholesalers Question Inflexibility in Official Pricing, Sees Limit to Addressing Rising Costs
September 30, 2022
-
Crecon President Sounds Alarm over Hollowing-Out of Domestic Manufacturing
September 30, 2022
-
Trade Group Calls for New Pricing Model for Regenerative Medicine Products
September 30, 2022
-
2% Buffer Zone Has Multiple Functions, Should Not Be Reduced: JPWA
September 30, 2022
-
Pharma Industry Faces Hurdles in Getting Medical Circle to Accept Softer Drug Price Cut Plan
September 28, 2022
-
Cost Rates of Drugs in Japan Worsen on Inflation, Weaker Yen: FPMAJ Survey
September 26, 2022
-
Japan, US, European Trade Groups Eye Introduction of “Official Margins” in Price Revision Review
September 26, 2022
-
Academic Experts Throw Candid Questions on Industry Structure, Pricing: Hearing
September 26, 2022
-
Japan Generic Industry Prods Govt to Raise Drug Prices to Ensure Stable Supply
September 26, 2022
-
Revamped Expert Panel Holds Industry Hearing, Discussions Center on Drug Price Gap
September 26, 2022
-
Expand Range of Essential Drugs, Limit Coverage of Off-Year Re-Pricing: FPMAJ Member Associations
September 26, 2022
-
MHLW Retools New Expert Panel, Industry Hearing Set for Sept. 22
September 21, 2022
-
Generic Industry Has High Hopes on New Expert Panel; Will Its Recommendations Ease Impact of Annual Re-Pricing?
September 9, 2022
-
Experts Raise Alarm on Declining Attractiveness of Japan Market: New Panel
September 1, 2022
-
New Expert Panel on Drug Distribution and Pricing Boots Up; 2-Step Proposals Eyed for Off-Year Revision, 2024 Reform
September 1, 2022
-
Launch of New Expert Panel Nears, How Can It Make Its Proposal Productive?
August 25, 2022
-
1st Meeting of New Drug Distribution and Pricing Panel Set for Aug. 31
August 25, 2022
-
New Expert Panel to Issue Proposals for 2023, 2024 Price Revisions; Official Spearheading Debate Prods Industry to Speak Up
July 29, 2022
-
MHLW Eyes Expert Panel Launch This Summer for Drug Distribution and Pricing: Official
July 19, 2022
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…